According to these results and in the light of the emerging role of PARP inhibitors in the treatment of triple negative breast cancer, there is a solid scientific rationale for the use of these molecules as maintenance therapy even in patients with TNBC. This evidence concerns the gene PARP1 and triple-negative breast carcinoma.